Real world evidence (RWE) has become increasingly important in the pharmaceutical and life sciences industry in recent years. With large volumes of real-world patient data now available from electronic health records, claims and billing data, patient registries, and other healthcare data sources, companies are able to generate RWE to supplement results from clinical trials. This data provides insights into how treatments are used and their effectiveness outside of tightly controlled clinical trial settings.

RWE is being utilized across the product lifecycle from drug discovery and development through commercialization. In the early R&D phase, RWE can help identify new targets and biomarkers. It also allows companies to evaluate the benefits and risks of interventions in broader patient populations than typically enrolled in clinical trials. Regulators such as the FDA also accept RWE for expanding drug labels, demonstrating long-term safety and effectiveness, and supporting reimbursement decisions.

Pharmaceutical and Life Sciences Real World Evidence - https://www.coherentmi.com/blog/pharmaceutical-and-life-sciences-real-world-evidence-poised-for-significant-growth-126